First Product to Enter the Market under Partnership Agreement which Includes Development and Distribution of Six Ophthalmic and Otic ANDA Products
Maple Grove, MN and Athens, Greece – May 27, 2021 – Upsher-Smith Laboratories, LLC ... Read More
Osaka, Japan – February 15, 2021 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for eight generic drugs with 20 ... Read More
Recipients Chosen for Their Dedication to Patients and Commitment to Advancing Pharmacy Care
Maple Grove, MN – February 8, 2021 – Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are pleased ... Read More
Now Offers Commercially Insured Patients $0 Copay and Free Home Delivery for Acute and Preventive Migraine Treatment Options
Maple Grove, MN – February 1, 2021 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that commercially insured migraine ... Read More
Osaka, Japan – January 28, 2021 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) announced that it has entered into an exclusive development and marketing agreement with Neurolief Ltd. (Neurolief, ... Read More
Maple Grove, MN – December 15, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Ramelteon Tablets, 8 mg. Upsher-Smith’s product is AB-rated to the branded product, ROZEREM® (ramelteon) tablets.* Ramelteon tablets are ... Read More
